Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

  • Du, Wenjuan
  • Hurdiss, Daniel L.
  • Drabek, Dubravka
  • Mykytyn, Anna Z.
  • Kaiser, Franziska K.
  • González-Hernandez, Mariana
  • Muñoz-Santos, Diego
  • Lamers, Mart M.
  • Haperen, Rien van
  • Li, Wentao
  • Drulyte, Ieva
  • Wang, Chunyan
  • Solá Gurpegui, Isabel
  • Armando, Federico
  • Beythien, Georg
  • Ciurkiewicz, Malgorzata
  • Baumgärtner, Wolfgang
  • Guilfoyle, Kate
  • Smits, Tony
  • Lee, Joline van der
  • Kuppeveld, Frank J. M. van
  • Amerongen, Geert van
  • Haagmans, Bart L.
  • Enjuanes Sánchez, Luis
  • Osterhaus, Albert D. M. E.
  • Grosveld, Frank
  • Bosch, Berend Jan
The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which displays striking immune escape potential. Many of its mutations localize to the spike protein ACE2 receptor-binding domain, annulling the neutralizing activity of most therapeutic monoclonal antibodies. Here we describe a receptor-blocking human monoclonal antibody, 87G7, that retains ultrapotent neutralization against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) Variants-of-Concern (VOCs). Structural analysis reveals that 87G7 targets a patch of hydrophobic residues in the ACE2-binding site that are highly conserved in SARS-CoV-2 variants, explaining its broad neutralization capacity. 87G7 protects mice and/or hamsters against challenge with all current SARS-CoV-2 VOCs. Our findings may aid the development of sustainable antibody-based strategies against COVID-19 that are more resilient to SARS-CoV-2 antigenic diversity., The MANCO project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003651). This work made use of the Dutch national e infrastructure with the support of the SURF Cooperative using grant no. EINF-2453. This research was funded by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) - 398066876/GRK 2485/1; BMBF (Federal Ministry of Education and Research) project entitled RAPID (Risk assessment in re-pandemic respiratory infectious diseases), 01KI1723G, Ministry of Science and Culture of Lower Saxony in Germany (14 - 76103-184 CORONA-15/20), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern

  • Du, Wenjuan
  • Hurdiss, Daniel L.
  • Drabek, Dubravka
  • Mykytyn, Anna Z.
  • Kaiser, Franziska K.
  • González-Hernandez, Mariana
  • Muñoz-Santos, Diego
  • Lamers, Mart M.
  • Haperen, Rien van
  • Li, Wentao
  • Drulyte, Ieva
  • Wang, Chunyan
  • Solá Gurpegui, Isabel
  • Armando, Federico
  • Beythien, Georg
  • Ciurkiewicz, Malgorzata
  • Baumgärtner, Wolfgang
  • Guilfoyle, Kate
  • Smits, Tony
  • Lee, Joline van der
  • Kuppeveld, Frank J. M. van
  • Amerongen, Geert van
  • Haagmans, Bart L.
  • Enjuanes Sánchez, Luis
  • Osterhaus, Albert D. M. E.
  • Grosveld, Frank
  • Bosch, Berend Jan
The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which displays striking immune escape potential through mutations at key antigenic sites on the spike protein. Many of these mutations localize to the spike protein ACE2 receptor-binding domain, annulling the neutralizing activity of therapeutic antibodies that were effective against other Variants of Concern (VOCs) earlier in the pandemic. Here, we identified a receptor-blocking human monoclonal antibody, 87G7, that retained potent in vitro neutralizing activity against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) VOCs. Using cryo-electron microscopy and site-directed mutagenesis experiments, we showed that 87G7 targets a patch of hydrophobic residues in the ACE2-binding site that are highly conserved in SARS-CoV-2 variants, explaining its broad neutralization capacity. 87G7 protected mice and/or hamsters prophylactically against challenge with all current SARS-CoV-2 VOCs, and showed therapeutic activity against SARS-CoV-2 challenge in both animal models. Our findings demonstrate that 87G7 holds promise as a prophylactic or therapeutic agent for COVID-19 that is more resilient to SARS-CoV-2 antigenic diversity., The MANCO project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101003651). This work made use of the Dutch national e-infrastructure with the support of the SURF Cooperative using grant no. EINF-2453. This research was funded by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) -398066876/GRK 2485/1; BMBF (Federal Ministry of Education and Research) project entitled RAPID (Risk assessment in re-pandemic respiratory infectious diseases), 01KI1723G, Ministry of Science and Culture of Lower Saxony in Germany (14 - 76103-184 CORONA-15/20), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nature of viruses and pandemics: Coronaviruses

  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
  • Zúñiga Lucas, Sonia
  • Honrubia, José M.
  • Bello-Pérez, Melissa
  • Sanz-Bravo, Alejandro
  • González-Miranda, E.
  • Hurtado-Tamayo, Jesús
  • Requena-Platek, Ricardo
  • Wang, Li
  • Muñoz-Santos, Diego
  • Sánchez, Carlos M.
  • Esteban, Ana
  • Ripoll-Gómez, Jorge
Coronaviruses (CoVs) have the largest genome among RNA viruses and store large amounts of information without genome integration as they replicate in the cell cytoplasm. The replication of the virus is a continuous process, whereas the transcription of the subgenomic mRNAs is a discontinuous one, involving a template switch, which resembles a high frequency recombination mechanism that may favor virus genome variability. The origin of the three deadly human CoVs SARS-CoV, MERS-CoV and SARS-CoV-2 are zoonotic events. SARS-CoV-2 has incorporated in its spike protein a furine proteolytic site that facilitates the activation of the virus in any tissue, making this CoV strain highly polytropic and pathogenic. Using MERS-CoV as a model, a propagation-deficient RNA replicon was generated by removing E protein gene (essential for viral morphogenesis and involved in virulence), and accessory genes 3, 4a, 4b and 5 (responsible for antagonism of the innate immune response) to attenuate the virus: MERS-CoV-Δ[3,4a,4b,5,E]. This RNA replicon is strongly attenuated and elicits sterilizing protection after a single immunization in transgenic mice with the receptor for MERS-CoV, making it a promising vaccine candidate for this virus and an interesting platform for vector-based vaccine development. A strategy could be developed for the design of RNA replicon vaccines for other human pathogenic coronaviruses., This work was supported by grants from the Government of Spain (PID2019-107001RB-I00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1-202020E079), the CSIC (PIE_INTRAMURAL-202020E043), the European Commission (ISOLDA_848166 H2020-SC1-2019-Two-Stage-RTD, RIA; MANCO_101003651 H2020-SC1-PHE-CORONAVIRUS-2020 RIA), and the U.S. National Institutes of Health (NIH_2P01AI060699)., Peer reviewed